{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:51:50Z","timestamp":1753890710343,"version":"3.41.2"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ceritinib is used for the treatment of patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), who are at the risk of developing bone metastasis. During bone metastasis, tumor cells release factors that induce osteoclast formation, resulting in osteolysis. However, the effect of ceritinib on osteoclast formation remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Osteoclastogenesis was induced to assess the effect of ceritinib on osteoclast formation and osteoclast-specific gene expression. Western blotting was used to examine the molecular mechanisms underlying the effect of ceritinib on osteoclast differentiation. An <jats:italic>in vivo<\/jats:italic> ovariectomized mouse model was established to validate the effect of ceritinib in suppressing osteoclast formation and preventing bone loss.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The differentiation of osteoclasts and the expression of osteoclast-specific genes were inhibited upon ceritinib stimulation. Ceritinib suppressed Akt and p65 phosphorylation during the receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis. The administration of ceritinib to ovariectomized mice ameliorated trabecular bone loss by inhibiting osteoclast formation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ceritinib is beneficial in preventing bone loss by suppressing osteoclastic Akt and nuclear factor \u03baB (NF-\u03baB) signaling.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.939959","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T06:12:40Z","timestamp":1667887960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-\u03baB-induced osteoclast formation"],"prefix":"10.3389","volume":"13","author":[{"given":"Wenxin","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiankun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kewei","family":"Rong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1021\/jm400402q","article-title":"Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro- n 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- n 4-(2-(isopropylsulfonyl) phenyl)pyrimidine-2,4","volume":"56","author":"Marsilje","year":"2013","journal-title":"J Med Chem"},{"key":"B2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/b978-0-12-800886-7.00023-6","article-title":"Molecular testing in lung cancer","author":"Shiau","year":"2017","journal-title":"Diagn Mol Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1311107","article-title":"Ceritinib in ALK -rearranged non\u2013Small-Cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): A randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0776-2","article-title":"Role and targeting of anaplastic lymphoma kinase in cancer","volume":"17","author":"Della Corte","year":"2018","journal-title":"Mol Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","article-title":"The role of the ALK receptor in cancer biology","volume":"27","author":"Hallberg","year":"2016","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2174\/092986712803833209","article-title":"Bone metastases and non-small cell lung cancer: From bisphosfonates to targeted therapy","volume":"19","author":"Rossi","year":"2012","journal-title":"Curr Med Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-011-9398-4","article-title":"Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292","volume":"28","author":"Furugaki","year":"2011","journal-title":"Clin Exp Metastasis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.31768\/2312-8852.2018.40(2):136-139","article-title":"The state of bone metabolism in lung cancer patients","volume":"40","author":"Dumanskiy","year":"2018","journal-title":"Exp Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1323","article-title":"Effect of bisphosphonates on pain and quality of life in patients with bone metastases","volume":"6","author":"Costa","year":"2009","journal-title":"Nat Clin Pract Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.lungcan.2009.08.020","article-title":"Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates","volume":"67","author":"Langer","year":"2010","journal-title":"Lung Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.10.001","article-title":"Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non-small cell lung cancer and bone metastases: A systematic review","volume":"11","author":"Hendriks","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41574-019-0282-7","article-title":"A road map for understanding molecular and genetic determinants of osteoporosis","volume":"16","author":"Yang","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B14","article-title":"Osteoblast and osteoclast cell number and cell activity in postmenopausal osteoporosis","volume":"12","author":"Gruber","year":"1986","journal-title":"Miner Electroly Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An overview and management of osteoporosis","volume":"4","author":"Sozen","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.366","article-title":"Failure of estrogen plus progestin therapy for prevention","volume":"288","author":"Fletcher","year":"2002","journal-title":"J Am Med Assoc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women\u2019s health initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"J Am Med Assoc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33392","article-title":"RelA\/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice","volume":"118","author":"Vaira","year":"2008","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2008.10.146","article-title":"NF-\u03baB functions in osteoclasts","volume":"378","author":"Soysa","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-012-0109-0","article-title":"Signaling pathways affecting skeletal health","volume":"10","author":"Marie","year":"2012","journal-title":"Curr Osteoporos Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101254","article-title":"Akt induces osteoclast differentiation through regulating the GSK3\u03b2\/NFATc1 signaling cascade","volume":"188","author":"Moon","year":"2012","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/369411a0","article-title":"Requirement for ras in raf activation is overcome by targeting raf to the plasma membrane","volume":"369","author":"Leevers","year":"1994","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.7811320","article-title":"Activation of raf as a result of recruitment to the plasma membrane","volume":"264","author":"Stokoe","year":"1994","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/358417a0","article-title":"Raf-1 activates MAP kinase-kinase","volume":"358","author":"Kyriakis","year":"1992","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.148.2.333","article-title":"Reciprocal role of ERK and NF-\u03baB pathways in survival and activation of osteoclasts","volume":"148","author":"Miyazaki","year":"2000","journal-title":"J Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.7.1198","article-title":"Role of Osteoclast Extracellular Signal-Regulated Kinase (ERK) in Cell Survival and Maintenance of Cell Polarity","volume":"18","author":"Nakamura","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3917","article-title":"Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice","volume":"21","author":"Dankbar","year":"2015","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-742","article-title":"Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer","volume":"14","author":"Eswaraka","year":"2014","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000489672","article-title":"Cortical or trabecular bone: What\u2019s the difference","volume":"47","author":"Ott","year":"2018","journal-title":"Am J Nephrol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: Clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeketal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/02841860600635870","article-title":"Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-\u03baB ligand (RANKL)\/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton","volume":"46","author":"Mountzios","year":"2007","journal-title":"Acta Oncol (Madr)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25843","article-title":"A novel KIF5B-ALK variant in nonsmall cell lung cancer","volume":"117","author":"Wong","year":"2011","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.04.004","article-title":"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant","volume":"19","author":"Sakamoto","year":"2011","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.28162","article-title":"Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer","volume":"15","author":"Ji","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-018-0059-0","article-title":"The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas","volume":"4","author":"Miyazaki","year":"2018","journal-title":"Cell Death Discovery"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v96.13.4319","article-title":"Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase\/Akt antiapoptotic signaling pathway","volume":"96","author":"Bai","year":"2000","journal-title":"Blood"},{"key":"B39","article-title":"Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin\/anaplastic lymphoma kinase-mediated lymphomagenesis","volume":"61","author":"Slupianek","year":"2001","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/43354","article-title":"Apoptosis: Akt is more than just a bad kinase","volume":"401","author":"Khwaja","year":"1999","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210546","article-title":"Activation of NF-\u03baB by akt upregulates snail expression and induces epithelium mesenchyme transition","volume":"26","author":"Julien","year":"2007","journal-title":"Oncogene"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0609-8","article-title":"Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma","volume":"16","author":"Inoue","year":"2017","journal-title":"Mol Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tibs.2004.11.009","article-title":"Phosphorylation of NF-\u03baB and I\u03baB proteins: Implications in cancer and inflammation","volume":"30","author":"Viatour","year":"2005","journal-title":"Trends Biochem Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.939959\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T06:12:43Z","timestamp":1667887963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.939959\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":43,"alternative-id":["10.3389\/fendo.2022.939959"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.939959","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"article-number":"939959"}}